In the endeavour of protecting Intellectual Property rights, pharmaceutical companies are closely following the evolvement of work practices in patenting, litigation and deal structuring. The SMi group’s Pharmaceutical Intellectual Property Conference will examine key aspects of the industry – patent infringement disputes, legal advancements and regulatory frameworks. How will this conference benefit me? |  |
Q: How will the shift towards Biological Pharmaceuticals impact the legal practice? A: SHIFTING TOWARDS BIOLOGICS – Reviewing practices in patenting and litigation Q: What thought processes should be applied to risk management in court litigation? A: RISK MANAGEMENT IN COURT LITIGATION – Applying a strategic thought process to assess the prospects in litigation Q: What measures should be taken to protect IP rights in a global arena? A: MAINTAINING IP RIGHTS IN THE GLOBAL ARENA - Proactive protection in multiple markets With presentations from key industry experts: - Jim Shehan, Vice President, General Counsel, Novo Nordisk
- Alexandre Mencik, Senior Legal Counsel, Amgen
- Dr Frank Burkert, European Patent Attorney, Bayer Healthcare
- Alasdair Moodie, Assistant General Counsel, Cambridge Antibody Technology
- Thomas F. Fleming, Partner, IP Litigation, Kaye Scholar LLP
- Peter Bogaert, Partner, Covington & Burling LLP
- Dr Duncan Curley, Partner, IP, McDermott, Will & Emery
- Monika Derecque-Pois, Director General, GIRP
- Christine Hänle, Corporate Purchasing Ethical Manager, Celesio AG
Designed to meet industry needs, the conference creates the perfect setting for prolific exchanges of ideas and networking opportunities.
|
Events Home Page
